BCL2L1 and leukemia: Dual Inhibitors: Ongoing research has focused on developing compounds that can simultaneously inhibit multiple anti-apoptotic proteins (e.g., dual Bcl-2/Bcl-XL inhibitors) to prevent resistance and promote sustained apoptosis in leukemia cells [63].